Functional characterization of a novel FGFR1OP-RET rearrangement in hematopoietic malignancies

The Structural Basis for Control of Eukaryotic Protein Kinases

(2012) Jane A. Endicott et al.   Annual Review of Biochemistry

Essential role for Stat5a/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2V617F in mice

(2012) C. Walz et al.   BLOOD

Effects ofTET2mutations on DNA methylation in chronic myelomonocytic leukemia

(2012) Jumpei Yamazaki et al.   Epigenetics

Mutations in epigenetic regulators in myelodysplastic syndromes

(2012) Gorica Nikoloski et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

RET fusion genes are associated with chronic myelomonocytic leukemia and enhance monocytic differentiation

(2012) P Ballerini et al.   LEUKEMIA

The classification of MDS: From FAB to WHO and beyond

(2012) James Vardiman   LEUKEMIA RESEARCH

Myeloproliferative neoplasms 2012: The John M. Bennett 80th birthday anniversary lecture

(2012) Ayalew Tefferi   LEUKEMIA RESEARCH

Myeloproliferative disorder FOP-FGFR1 fusion kinase recruits phosphoinositide-3 kinase and phospholipase Cγ at the centrosome

(2012) Hélène Lelièvre et al.   Molecular Cancer

Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies

(2012) Doron Lipson et al.   NATURE MEDICINE

KIF5B-RET fusions in lung adenocarcinoma

(2012) Takashi Kohno et al.   NATURE MEDICINE

RET, ROS1 and ALK fusions in lung cancer

(2012) Kengo Takeuchi et al.   NATURE MEDICINE

Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A

(2011) A. M. Jankowska et al.   BLOOD

Mouse models of myeloproliferative neoplasms: JAK of all grades

(2011) J. Li et al.   Disease Models & Mechanisms

Prognostic Significance of ASXL1 Mutations in Patients With Myelodysplastic Syndromes

(2011) Felicitas Thol et al.   JOURNAL OF CLINICAL ONCOLOGY

Recurrent DNMT3A mutations in patients with myelodysplastic syndromes

(2011) M J Walter et al.   LEUKEMIA

Transformation of a Chronic Myeloproliferative Neoplasm to Acute Myelogenous Leukemia: Does Anything Work?

(2011) Madappa N. Kundranda et al.   Current Hematologic Malignancy Reports

JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia

(2010) J. Li et al.   BLOOD

ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia

(2010) Véronique Gelsi-Boyer et al.   BRITISH JOURNAL OF HAEMATOLOGY

Cell Signaling by Receptor Tyrosine Kinases

(2010) Mark A. Lemmon et al.   CELL

Insights into the stem cells of chronic myeloid leukemia

(2010) I Sloma et al.   LEUKEMIA

Tumor-intrinsic and -extrinsic roles of c-Kit: mast cells as the primary off-target of tyrosine kinase inhibitors

(2010) P Pittoni et al.   ONCOGENE

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

(2009) J. W. Vardiman et al.   BLOOD

Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML

(2009) A Tefferi et al.   LEUKEMIA

Acquired mutations in TET2 are common in myelodysplastic syndromes

(2009) Saskia M C Langemeijer et al.   NATURE GENETICS

Roles for deregulated receptor tyrosine kinases and their downstream signaling molecules in hematologic malignancies

(2008) Itaru Matsumura et al.   CANCER SCIENCE

Treatment of chronic myeloid leukemia in blast crisis

(2008) R. Hehlmann et al.   HAEMATOLOGICA